CN106540279A - A kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent and preparation method thereof - Google Patents
A kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent and preparation method thereof Download PDFInfo
- Publication number
- CN106540279A CN106540279A CN201611057761.6A CN201611057761A CN106540279A CN 106540279 A CN106540279 A CN 106540279A CN 201611057761 A CN201611057761 A CN 201611057761A CN 106540279 A CN106540279 A CN 106540279A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- pharmaceutical preparation
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002496 gastric effect Effects 0.000 title claims abstract description 34
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 30
- 239000002961 echo contrast media Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 20
- 210000000582 semen Anatomy 0.000 claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 44
- 241000756943 Codonopsis Species 0.000 claims abstract description 24
- 241000237524 Mytilus Species 0.000 claims abstract description 24
- 241000217407 Margaritifera Species 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims description 37
- 239000008187 granular material Substances 0.000 claims description 33
- 239000002994 raw material Substances 0.000 claims description 23
- 239000006071 cream Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 241000490567 Pinctada Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000007086 side reaction Methods 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 description 28
- 239000002872 contrast media Substances 0.000 description 23
- 238000002601 radiography Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 11
- 229960002986 dinoprostone Drugs 0.000 description 11
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000007107 Stomach Ulcer Diseases 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 201000005917 gastric ulcer Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical group N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229960000381 omeprazole Drugs 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000002318 cardia Anatomy 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000003453 lung abscess Diseases 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004203 pyloric antrum Anatomy 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 201000005661 acute cystitis Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000010271 massa medicata fermentata Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent and preparation method thereof, in prescription containing weight portion is：Concha Margaritifera, Mytilus, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Folium Malvae, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Herba Thesii, Herba Euphorbiae supinae, Radix Codonopsis lanceolatae, Herba Tropaeoli.The present invention provides the preparation method of two kinds of routines, it is easy to operate, industrialized production can be carried out, water decoction can be adapted to individual patients and take, the therapeutic effect of the medicine of the present invention has curative effect high, the features such as instant effect, short treating period, and expense is low, safety non-toxic side reaction, with higher social value, find through clinical trial, pharmaceutical preparation of the present invention has a significant effect.
Description
Technical field
The invention belongs to field of medicaments, more particularly to a kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent and preparation method thereof.
Background technology
The continuous development of human diseasess promotes the continuous renewal of detection meanss, contrast agent one dazzling " star ", contrast agent
(also known as contrast medium, contrastmedia) is to inject (or taking) to tissue or organ to strengthen Imaging Study effect
Chemicalss.The density of these products is higher or lower than surrounding tissue, and the contrast of formation is with some apparatus display images.Such as X
The conventional Operand of line observation, barium sulfate etc..
Ultrasonic image diagnosis are one of important diagnostic methods in medical science.Ultrasound wave has three big effects to material：One is machinery
Effect, as ultrasonic energy is huge, often makes material particle make altofrequency mechanical vibration, thus produces and smash, condense, stirring
Effect.Two is warm-heat effect, and when material, its energy is absorbed ul-trasonic irradiation by material, thus it is existing to raise mass temperature
As.Three is cavitation, when ul-trasonic irradiation is on liquid, the weak region (if any microscopic bubble etc.) of liquid internal stress by
Become sparse in acoustic pressure great variety, at this moment around under fluid molecule pulling force effect, form a little cavity, it is as empty
Change is acted on.
As human intestines and stomach belongs to hollow organ, generally, coat of the stomach level can not be shown well using color ultrasound.Help
The use of shadow agent can make full form, gastral cavity size, coat of the stomach level, emptying time and the stomach that can show stomach well of gastral cavity
Diseased region, while the pathological changes situation of small intestinal and colon can also be shown.The traditional Chinese medical science has incomparable as traditional motherland's medical science
Advantage.
Chinese medicine composition gradually extensively gets up as the application of contrast agent at present, such as Chinese invention patent application number：
01128137.5 provides one kind is used for color gastrointestinal ultrasonic contrast medium, by 1 part of Margarita, 1 part of Concha Haliotidis, 1 part of Endoconcha Sepiae, Pseudobulbus Bletillae (Rhizoma Bletillae)
1 part composition, human body gastritis of clarifying a diagnosis, gastric ulcer, gastric cancer, gastroptosis, prolapse of gastric mucosa, duodenal bulbar inflammation, 12
The disease such as cancerous protuberance at duodenum 12 duodenal bulbar ulcer, phase morning, noon and afternoon gastrointestinal tumor, esophagus upper-lower section and cardia.
Chinese invention patent application number 200810238127.1 discloses Chinese medicine contrast agent and its preparation that a kind of B ultrasonic is used
Method, its contrast agent include the various raw materials of following portions by weight ratio:10～20 parts of Concha Haliotidis, 10～20 parts of Concha Erosariae seu Cypraeae, Massa Medicata Fermentata
10～20 parts, 10～20 parts of Radix Codonopsis, 10～20 parts of the Rhizoma Atractylodis Macrocephalae, 10～20 parts of Poria, 10～20 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae), 10～20 parts of Herba Patriniae,
10～20 parts of the Radix Linderae, 10～20 parts of the Radix Aucklandiae.
Chinese invention patent application number 201210364551.7 has supplied a kind of Chinese medicine gastrointestinal contrast agent and its system for B ultrasonic
Preparation Method, Chinese medicine include following raw medicinal material：Fructus Foeniculi, Rhizoma Alpiniae Officinarum, Rhizoma Cyperi, the Radix Linderae, Endoconcha Sepiae, Pericarpium Citri Reticulatae Viride, Massa Medicata Fermentata, Fructus Hordei Germinatus,
Fructus Aurantii Immaturus, Radix Et Rhizoma Rhei, Natrii Sulfas, Cortex Magnoliae Officinalis, the Radix Aucklandiae, Fructus Amomi, Herba Pogostemoniss, Fructus Citri Sarcodactylis, Fructus Crataegi, Semen Raphani, Concha Arcae (calcined), Fructus Evodiae, the Rhizoma Pinelliae, Bin
The bulky, Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Nardostachyos and Bulbus Fritillariae Thunbergii.
A kind of gastrointestinal tract contrast mediums of Chinese patent CN201510487240, it is disclosed that 50～70 parts of barium sulfate, Chinese medicine
300～500 parts of 25～35 parts of extract, 50～80 parts of Mel and water；Wherein Chinese medicine extract prepared by following raw material of Chinese medicine and
Into：20～30 parts of Herba Damnacanthi, 20～30 parts of Radix Berchemiae Giraldianae, native 20～30 parts of Radix Adenophorae (Radix Glehniae), 10～15 parts of white residual flower, 10～15 parts of the Rhizoma Pinelliae,
10～15 parts of Monas cuspurpureus Went, 10～15 parts of Herba Asplenii Incisi, 10～15 parts of Radix Rehmanniae, 10～15 parts of the Fructus Sophorae, 10～15 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae), the Radix Astragali 5～
10 parts, 5～10 parts of Radix Bupleuri, the present invention have gastrointestinal peristalsis inhibition it is too fast, auxiliary barium meal swallow, nourishes gastrointestinal tract and suppression stomach go out
The advantage of blood.
Conventional contrast agent is mainly barium sulfate and Operand at present, and so existing research has confirmed that existing contrast agent is used
Amount is the independent hazard factor for causing contrast agent nephropathy.In addition contrast agent patient Herba Urticae Cannabinae can also be caused to examine, angioedema, larynx
The idiosyncratic reactions such as cephaledema, bronchospasm, serious blood pressure drops and sudden death.This kind of contrast agent increases to gastrointestinal tract simultaneously
Add extra burden, increased the pain of patient.
The content of the invention
For the defect of prior art, the present invention be directed to the present situation for the treatment of at present, there is provided a kind of gastrointestinal color ultrasound contrast agent
Pharmaceutical preparation and preparation method thereof, and have no toxic side effect, effect is good.
Specifically, concrete scheme of the invention is realized in：
First, inventor provides a kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent according to drug matching experience, in prescription
The Chinese medicine ingredients for containing are：Concha Margaritifera, Mytilus, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Folium Malvae, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae,
Herba Thesii, Herba Euphorbiae supinae, Radix Codonopsis lanceolatae, Herba Tropaeoli.
Further, inventor provides a kind of pharmaceutical preparation for gastrointestinal color ultrasound contrast agent according to drug matching experience,
Each raw material dosage of prescription all has preferable curative effect in the weight portion scope of the present invention, and described formula and weight portion are：
Concha Margaritifera 15-25 parts, Mytilus 15-30 parts, Rhizoma Chuanxiong 12-16 parts, Radix Sanguisorbae 6-12 parts, Semen Cuscutae 5-12 parts, Semen Euryaless 4-11 parts, Semen Abutili
Leaf 10-20 parts, Semen Ziziphi Spinosae 8-15 parts, Radix Glycyrrhizae 6-12 parts, Radix Scutellariae 5-10 parts, Herba Thesii 7-14 parts, Herba Euphorbiae supinae 3-8 parts, Radix Codonopsis lanceolatae
6-11 parts, Herba Tropaeoli 6-14 parts.
The formula of above-mentioned weight portion is carried out preferably, reaching superior technique effect, preferred formula is：Concha Margaritifera 18
It is part, 22 parts of Mytilus, 14 parts of Rhizoma Chuanxiong, 9 parts of Radix Sanguisorbae, 8.5 parts of Semen Cuscutae, 7.5 parts of Semen Euryaless, 15 parts of Folium Malvae, 12.5 parts of Semen Ziziphi Spinosae, sweet
9 parts of grass, 7.5 parts of Radix Scutellariae, 10.5 parts of Herba Thesii, 6 parts of Herba Euphorbiae supinae, 8 parts of Radix Codonopsis lanceolatae, 10 parts of Herba Tropaeoli.
Or：
20 parts of Concha Margaritifera, 20 parts of Mytilus, 13 parts of Rhizoma Chuanxiong, 10 parts, 9.5 parts of Semen Cuscutae, 7.5 parts of Semen Euryaless, 16 parts of Folium Malvae,
13.5 parts of Semen Ziziphi Spinosae, 10 parts of Radix Glycyrrhizae, 8.5 parts of Radix Scutellariae, 9.5 parts of Herba Thesii, 6.5 parts of Herba Euphorbiae supinae, 8.5 parts of Radix Codonopsis lanceolatae, Herba Tropaeoli 11
Part.
In pharmaceutical preparation described above, the Chinese medicine for being used uses its conventional medicinal part to be used as medicine, in being used
Pharmaceutical quantities rationally, for there is preferable effect for gastrointestinal contrast agent after all medicines share.
The function of each taste Chinese crude drug used in the pharmaceutical preparation of the treatment of the present invention is as follows：
Concha Margaritifera：Acrid in the mouth, it is mild-natured.
Indication：Heat-clearing and toxic substances removing, solution administration.For enteritis, lung abscess, tonsillitiss, middle administration, acute mastitiss, lymph
Knot tuberculosis, acute cystitis.
Mytilus：Sweet in the mouth, it is warm in nature.
Indication：Qi-restoratives, removes irritable feverish sensation in the chest, drop borax poison.
Rhizoma Chuanxiong：Acrid in the mouth, it is warm in nature.
Return through：Return liver, gallbladder, pericardium channel.
Indication：Blood-activating and qi-promoting, wind-expelling pain-stopping.For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen stomachache, chest side of body shouting pain are fallen
Flutter and swell and ache, have a headache, rheumatic arthralgia.
Radix Sanguisorbae：It is bitter in the mouth, acid, puckery, it is slightly cold.
Indication：Cooling blood for hemostasis, removing toxic substances sore.For having blood in stool, hemorrhoidal bleeding, dysentery, metrorrhagia, burn due to hot liquid or fire, carbuncle sore tumefacting virus.
Semen Cuscutae：Sweet in the mouth, it is warm in nature.
Return through：Return liver, kidney, spleen channel.
Indication：Nourishing the liver and kidney, astringent sperm contracting urine are antiabortive, improving eyesight, antidiarrheal, for impotence and seminal emission, dripping urination, the enuresis
Frequent micturition, soreness of the waist and knees, blurred vision tinnitus, vaginal bleeding due to deficiency of the kidney during pregnancy, frequent fetal movement, spleen kidney deficiency are rushed down.
Semen Euryaless：It is sweet in the mouth, puckery, put down.
Return through：Returns spleen, kidney channel.
Indication：Supplementing the kidney to control the nocturnal, tonifying spleen and stopping diarrhea, tonifying spleen and stopping diarrhea.For emission, enuresis frequent micturition, insufficiency of the spleen chronic diarrhea, in vain
It is turbid, leukorrhagia
Folium Malvae：Sweet in the mouth, it is cold in nature.
Indication：Heat clearing away. water-filling, laxation.Control cough due to lung-heat, pyretic toxicity dysentery, jaundice, constipation and anuresis, erysipelas, incised wound.
Semen Ziziphi Spinosae：Sweet in the mouth is nontoxic.
Indication：Can pacify and the five internal organs, big reinforcing the heart spleen.Therefore blood not returns spleen, and the not peaceful person that dosses, it is multiplex it.
Radix Glycyrrhizae：Sweet in the mouth, it is mild-natured.
Return through：Enter spleen, stomach, the heart, lung meridian.
Indication：Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain.
Radix Scutellariae：Bitter in the mouth, it is cold in nature.
Return through：Return lung, gallbladder, spleen, large intestine, small intestine meridian.
Indication：Heat clearing and damp drying, eliminating fire and detoxication, hemostasis are antiabortive.For hygropyrexia, fever disease in summer vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness,
Dysentery, jaundice, cough due to lung-heat, hyperpyrexia excessive thirst, blood-head tells nosebleed, carbuncle sore tumefacting virus, frequent fetal movement.
Herba Thesii：Acrid in the mouth, it is mild-natured.
Indication：Heat-clearing and toxic substances removing, solution administration.For enteritis, lung abscess, tonsillitiss, middle administration, acute mastitiss, lymph
Knot tuberculosis, acute cystitis.
Herba Euphorbiae supinae：Acrid in the mouth, it is mild-natured.
Indication：Hemostasis, clearing away damp-heat, lactogenesis.Jaundice is controlled, is had loose bowels, infantile malnutrition, dysentery, hematuria, metrorrhagia, traumatic hemorrhage, breast
Juice is few, carbuncle sore tumefacting virus.
Radix Codonopsis lanceolatae：Sweet in the mouth, it is mild-natured
Return through：Returns spleen；Lung meridian
Indication：Supplementing QI and nourishing YIN；Removing toxic substances and promoting subsidence of swelling；Evacuation of pus；Lactogenesis.Main spiritlessness and weakness；Dizziness headache；Lung abscess；Acute mastitis；Intestinal
Future；Sore furuncle poison；Throat moth；Scrofula；Puerperal, breast was few；Leucorrhea；Venom.
Herba Tropaeoli：Acrid in the mouth, it is cool in nature.
Return through：The heart, kidney channel.
Effect and effect：Heat-clearing and toxic substances removing；Cooling blood for hemostasis.Main conjunctival congestion and swelling pain；Furuncle；Spit blood；Spitting of blood.
Color ultrasound gastrointestinal contrast agent of the present invention is oral administration, and its pharmaceutical dosage form can be powder, granule.
Through conscientious research, according to the reasonability of middle medical drugs, invention proposes this to prescription of the present invention to more than
The preparation method of bright gastrointestinal contrast agent, concretely comprises the following steps：
1) each crude drug is filtered out according to each proportioning raw materials, it is standby after remove impurity；
2) by Mytilus, Folium Malvae, Herba Thesii, Herba Euphorbiae supinae and Herba Tropaeoli be put into 1500ml it is pure in, after slow fire is fried open, then slowly
Decoct 30 minutes, pour out decocting liquid 500ml, add the pure water of 300ml, it is slow to decoct 20 minutes, then decocting liquid 200ml is poured out, add
The water of 500ml, is continued slow pan-fried 30 minutes, decocting liquid is poured out, is mixed with the front decocting liquid poured out twice and is stirred evenly；
3) step 2) raw material concentrating under reduced pressure obtains condensed cream；
4) appropriate Concha Margaritifera, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Radix Codonopsis lanceolatae are weighed respectively
80～120 sieves were dry, pulverize, mixed powder was obtained, it is standby
5), after condensed cream is dried, smashing and step 4) mixed powder mixs homogeneously, and obtains final product powder.
The preparation method of granule of the present invention is：
1) each crude drug is filtered out according to each proportioning raw materials, it is standby after remove impurity；
2) by Mytilus, Folium Malvae, Herba Thesii, Herba Euphorbiae supinae and Herba Tropaeoli be put into 1500ml it is pure in, after slow fire is fried open, then slowly
Decoct 30 minutes, pour out decocting liquid 500ml, add the pure water of 300ml, it is slow to decoct 20 minutes, then decocting liquid 200ml is poured out, add
The water of 500ml, is continued slow pan-fried 30 minutes, decocting liquid is poured out, is mixed with the front decocting liquid poured out twice and is stirred evenly；
3) step 2) raw material concentrating under reduced pressure obtains condensed cream；
4) appropriate Concha Margaritifera, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Radix Codonopsis lanceolatae are weighed respectively
80～120 sieves were dry, pulverize, mixed powder was obtained, it is standby
5), after condensed cream is dried, smashing and step 4) mixed powder mixs homogeneously, pelletizes, and vacuum drying, granulate obtain final product this
Invention granule.
Granule of the present invention often wraps weight 10g；The vacuum drying temperature of the present invention is controlled at 40-50 DEG C.
Usage and dosage of the granule of the present invention as color ultrasound gastrointestinal contrast agent：
By granule 10-20g of the present invention, it is dissolved in 100-300ml 70-80 DEG C boiled water, decoction being taken warmly.
Or granule 10-20g of the present invention, appropriate 70-80 DEG C of boiled water is added, is tuned into dense and burned, swallowed, then drink
100-300 temperature boiled water.
Pharmaceutical preparation of the present invention can serve as contrast agent use.
Purposes of the pharmaceutical preparation of the present invention in treatment gastrointestinal disease medicine is prepared is also used as to treat stomach
The medicine of ulcer is used.
Gastrointestinal disease of the present invention is gastric ulcer, acute gastritiss, chronic gastritiss or duodenal ulcer.
Pharmaceutical preparation of the present invention is used for, compared with prior art with following advantage：
(1) present invention provides the preparation method of two kinds of routines, easy to operate, can carry out industrialized production, and water decoction can
Taken with being adapted to individual patients, the therapeutic effect of the medicine of the present invention has curative effect high, instant effect, the features such as short treating period, and
Expense is low, safety non-toxic side reaction, with higher social value, finds through clinical trial, and pharmaceutical preparation of the present invention has
Obvious effect.
(2) pharmaceutical preparation of the present invention both can be used as contrast agent, again can be used as the medicine for the treatment of gastric ulcer
Thing is used.Use as contrast agent, easy to use, good in taste, the image clearly of formation, coat of the stomach clear layer is visible, each portion
Position focus is high-visible.
Specific embodiment
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Embodiment 1：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
15 grams of Concha Margaritifera, 15 grams of Mytilus, 12 grams of Rhizoma Chuanxiong, 6 grams of Radix Sanguisorbae, 5 grams of Semen Cuscutae, 4 grams of Semen Euryaless, 10 grams of Folium Malvae, acid
8 grams of Semen Ziziphi Spinosae, 6 grams of Radix Glycyrrhizae, 5 grams of Radix Scutellariae, 7 grams of Herba Thesii, 3 grams of Herba Euphorbiae supinae, 6 grams of Radix Codonopsis lanceolatae, 6 grams of Herba Tropaeoli.
Preparation method is：
1) each crude drug is filtered out according to each proportioning raw materials, it is standby after remove impurity；
2) by Mytilus, Folium Malvae, Herba Thesii, Herba Euphorbiae supinae and Herba Tropaeoli be put into 1500ml it is pure in, after slow fire is fried open, then slowly
Decoct 30 minutes, pour out decocting liquid 500ml, add the pure water of 300ml, it is slow to decoct 20 minutes, then decocting liquid 200ml is poured out, add
The water of 500ml, is continued slow pan-fried 30 minutes, decocting liquid is poured out, is mixed with the front decocting liquid poured out twice and is stirred evenly；
3) step 2) raw material concentrating under reduced pressure obtains condensed cream；
4) appropriate Concha Margaritifera, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Radix Codonopsis lanceolatae are weighed respectively
80～120 sieves were dry, pulverize, mixed powder was obtained, it is standby
5), after condensed cream is dried, smashing and step 4) mixed powder mixs homogeneously, pelletizes, and vacuum drying, granulate obtain final product this
Invention granule.
Embodiment 2：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
25 grams of Concha Margaritifera, 30 grams of Mytilus, 16 grams of Rhizoma Chuanxiong, 12 grams of Radix Sanguisorbae, 12 grams of Semen Cuscutae, 11 grams of Semen Euryaless, 20 grams of Folium Malvae,
15 grams of Semen Ziziphi Spinosae, 12 grams of Radix Glycyrrhizae, 10 grams of Radix Scutellariae, 14 grams of Herba Thesii, 8 grams of Herba Euphorbiae supinae, 11 grams of Radix Codonopsis lanceolatae, 14 grams of Herba Tropaeoli.
Preparation method is with embodiment 1.
Embodiment 3：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
18 grams of Concha Margaritifera, 22 grams of Mytilus, 14 grams of Rhizoma Chuanxiong, 9 grams of Radix Sanguisorbae, 8.5 grams of Semen Cuscutae, 7.5 grams of Semen Euryaless, Folium Malvae 15
Gram, 12.5 grams of Semen Ziziphi Spinosae, 9 grams of Radix Glycyrrhizae, 7.5 grams of Radix Scutellariae, 10.5 grams of Herba Thesii, 6 grams of Herba Euphorbiae supinae, 8 grams of Radix Codonopsis lanceolatae, Herba Tropaeoli 10
Gram.
Preparation method is with embodiment 1.
Embodiment 4：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
20 grams of Concha Margaritifera, 20 grams of Mytilus, 13 grams of Rhizoma Chuanxiong, 10 grams, 9.5 grams of Semen Cuscutae, 7.5 grams of Semen Euryaless, 16 grams of Folium Malvae,
13.5 grams of Semen Ziziphi Spinosae, 10 grams of Radix Glycyrrhizae, 8.5 grams of Radix Scutellariae, 9.5 grams of Herba Thesii, 6.5 grams of Herba Euphorbiae supinae, 8.5 grams of Radix Codonopsis lanceolatae, Herba Tropaeoli 11
Gram.
Preparation method is with embodiment 1.
Embodiment 5：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
15 grams of Concha Margaritifera, 15 grams of Mytilus, 12 grams of Rhizoma Chuanxiong, 6 grams of Radix Sanguisorbae, 5 grams of Semen Cuscutae, 4 grams of Semen Euryaless, 10 grams of Folium Malvae, acid
8 grams of Semen Ziziphi Spinosae, 6 grams of Radix Glycyrrhizae, 5 grams of Radix Scutellariae, 7 grams of Herba Thesii, 3 grams of Herba Euphorbiae supinae, 6 grams of Radix Codonopsis lanceolatae, 6 grams of Herba Tropaeoli.
Preparation method is：
1) each crude drug is filtered out according to each proportioning raw materials, it is standby after remove impurity；
2) by Mytilus, Folium Malvae, Herba Thesii, Herba Euphorbiae supinae and Herba Tropaeoli be put into 1500ml it is pure in, after slow fire is fried open, then slowly
Decoct 30 minutes, pour out decocting liquid 500ml, add the pure water of 300ml, it is slow to decoct 20 minutes, then decocting liquid 200ml is poured out, add
The water of 500ml, is continued slow pan-fried 30 minutes, decocting liquid is poured out, is mixed with the front decocting liquid poured out twice and is stirred evenly；
3) step 2) raw material concentrating under reduced pressure obtains condensed cream；
4) appropriate Concha Margaritifera, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Radix Codonopsis lanceolatae are weighed respectively
80～120 sieves were dry, pulverize, mixed powder was obtained, it is standby
5), after condensed cream is dried, smashing and step 4) mixed powder mixs homogeneously, and obtains final product powder.
Embodiment 6：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
25 grams of Concha Margaritifera, 30 grams of Mytilus, 16 grams of Rhizoma Chuanxiong, 12 grams of Radix Sanguisorbae, 12 grams of Semen Cuscutae, 11 grams of Semen Euryaless, 20 grams of Folium Malvae,
15 grams of Semen Ziziphi Spinosae, 12 grams of Radix Glycyrrhizae, 10 grams of Radix Scutellariae, 14 grams of Herba Thesii, 8 grams of Herba Euphorbiae supinae, 11 grams of Radix Codonopsis lanceolatae, 14 grams of Herba Tropaeoli.
Preparation method is with embodiment 5.
Embodiment 7：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
18 grams of Concha Margaritifera, 22 grams of Mytilus, 14 grams of Rhizoma Chuanxiong, 9 grams of Radix Sanguisorbae, 8.5 grams of Semen Cuscutae, 7.5 grams of Semen Euryaless, Folium Malvae 15
Gram, 12.5 grams of Semen Ziziphi Spinosae, 9 grams of Radix Glycyrrhizae, 7.5 grams of Radix Scutellariae, 10.5 grams of Herba Thesii, 6 grams of Herba Euphorbiae supinae, 8 grams of Radix Codonopsis lanceolatae, Herba Tropaeoli 10
Gram.
Preparation method is with embodiment 5
Embodiment 8：A kind of granule and its application for color ultrasound contrast agent, containing following raw material medicine：
20 grams of Concha Margaritifera, 20 grams of Mytilus, 13 grams of Rhizoma Chuanxiong, 10 grams, 9.5 grams of Semen Cuscutae, 7.5 grams of Semen Euryaless, 16 grams of Folium Malvae,
13.5 grams of Semen Ziziphi Spinosae, 10 grams of Radix Glycyrrhizae, 8.5 grams of Radix Scutellariae, 9.5 grams of Herba Thesii, 6.5 grams of Herba Euphorbiae supinae, 8.5 grams of Radix Codonopsis lanceolatae, Herba Tropaeoli 11
Gram.
Preparation method is with embodiment 5.
Embodiment 9：Animal model test
9.1st, animal model modeling and packet
Kunming rat 70, between body weight 180-220g, rat pre-operative anxiety 12h, normal group 5, sham operated rats 5,
Model group 15, omeprazole group 15,3 granule low dose group of embodiment (A groups) 15,3 granule high dose of embodiment
(B groups) organizes 15, freely drinks oresol (OregonRevisedStatutes, ORS), and ORS formula is Sodium Chloride 3.5
Gram, 2.5 grams of sodium bicarbonate, 1.5 grams of potassium chloride, 20 grams of glucose powder plus pure water to 1000ml.
Rat pre-operative anxiety, oresol 12-16h is freely drunk, 10% chloral hydrate (3.5mL/kg weights) muscle
Injecting anesthetic.With 0.5% iodophor disinfection rat abdomen skin, abdomen is opened along left rib lower edge, stomach is gently pulled out.
Clamped away from pyloric part 3mm body of stomach region with tweezers.0.18mL mineral oil and 0.02mL60% second inhaled in advance will
The stomach intracavity of closed zone is held in the syringe needle insertion of the syringe of acid under the arm, the stomach intracavity for holding closed zone under the arm inject 0.18mL mineral oil and
0.02mL60% acetic acid, suctions out acetic acid from stomach after 45s, then injects 2mL normal saline to stomach intracavity, suction out, with end after 1min
Only react.Stomach is resetted, penicillin sodium injection 0.1mL is instilled into otch and (800,000 unit penicillium sp is added with 4mL normal saline
Plain sodium, mixes), successively close abdomen.Sham-operated control group replaces acetic acid with the pure water that sterilizes.Postoperative Rat Fast, freely drink it is oral
Fluid infusion salt.Operate in art and gently rub and note sterile working, to reduce adhesion.
9.2nd, administering mode and operation
Postoperative Rat Fast 24h, freely drinks oresol.Normally enter drinking water after 12h, drinking water is pure water, daily
The Mus grain of input wants quantitative management.6.25 times calculating rat effective doses of the omeprazole (AstraZeneca) by people's dosage, i.e.,
1.04mg/kg body weight gavages, once a day；3 granule high and low dose group of embodiment of the present invention difference gastric infusion 4g/kg,
2g/kg, once a day, administration time is 9:00.10% chloral hydrate intraperitoneal anesthesia after Rat Fast, free water 24h
(3mL/kg weights).Open abdomen, ventral aorta blood sampling, not anticoagulant, 3 000r/min centrifugations 10min, collection after stand at low temperature 2h
The standby ELISA method detection of serum.Stomach is taken out, is cut off along greater gastric curvature, gastric mucosa is rinsed well by normal saline, take out stomach ulcer
Place, -70 DEG C of Refrigerator stores, in case ELISA method detection.
9.3rd, serum PG E2 content detection
Plus sample diluting liquid sequentially adds standard substance in hole as blank, remaining each hole adds 50 μ L of Sample serum,
The enzyme marking fluid of 100 μ L, 36 DEG C of incubation reactions 60min are added in standard sample wells and sample well.Washing liquid is cleaned 5 times and is added per hole afterwards
Enter each 50 μ L of substrate A, B liquid, 36 DEG C of Incubation in dark react 15min.50 μ L terminate liquids, terminating reaction are added per hole.The many work(of TECAN
Can microplate reader (Infinite M200, Austria) measure 450nm OD values.According to the dense of standard curve regression equation calculation sample
Degree.
9.4, gastric tissue homogenate PGE2 content detection
Rat gastric tissue is shredded after weighing, and is homogenized by 10mL/g plus normal saline, is obtained gastric tissue homogenate.Sample-adding product are dilute
Liquid is released as blank, standard substance each 50 μ L are sequentially added in hole, remaining each hole is loaded 50 μ L of product.10 are added in sample well
μ L biotin labeling liquid, adds the enzyme marking fluid of 100 μ L in standard sample wells and sample well.36 DEG C of incubation reactions 60min.Washing liquid
Cleaning adds substrate A, each 50 μ L of B liquid 5 times afterwards per hole.36 DEG C of Incubation in dark react 15min.50 μ L terminate liquids are added per hole, eventually
Only react.Determine 450nm OD values.According to the concentration of standard curve regression equation calculation sample.
9.5th, gastric tissue homogenate EGF content detection
Rat gastric tissue is shredded after weighing, and is homogenized by 10mL/g plus normal saline, is obtained gastric tissue homogenate.1 hole only adds
Sample diluting liquid sequentially adds standard substance each 50 μ L in hole as blank, and remaining each hole is loaded 50 μ L of product.Experimentation
With " 5.2 " item.
9.6th, statistical method
Using 13.0 softwares of SPSS, compare between group and use one factor analysis of variance, as a result withRepresent, with P<0.05
It is statistically significant for difference.
9.7th, result
1 PGE2, PGE2, EGF content such as following table of table
Note：
Compare with Normal group,##P ＜ 0.01；
Compare with model control group,@P ＜ 0.05,@@P ＜ 0.01；
Compare with omeprazole group,$P ＜ 0.05,$$P ＜ 0.01.
As it can be seen from table 1 by PGE2, PGE2, EGF content, model group is significantly lower than Normal group (P<0.01),
Show modeling success, and no significant difference between sham operated rats and Normal group, excluding operation affects；By comparing
PGE2, PGE2, EGF content, omeprazole group and granule of the present invention is low, high dose group PGE2, PGE2, EGF content is obvious
Less than model control group (P<0.01 or P<, and granule high dose group PGE2, PGE2 of the present invention, EGF contents are bright 0.05)
It is aobvious to be less than omeprazole group (P<0.05), the two is respectively provided with significant difference, is adapted to further genralrlization application.
Embodiment 10：Animal model test and experiment in vitro
Used in granule prepared by embodiment 1,2,4 and the granule alternate embodiments 9 for implementing 5,6,7,8 preparations
The granule of embodiment 3, repeats embodiment 9, as a result finds that granule prepared by embodiment 1,2,4,5,6,7,8 has preferably
Curative effect.
The clinical setting of embodiment 11, gastrointestinal contrast agent of the present invention in treatment gastric ulcer：
11.1, case selection：
Patients w ith peptic ulcer disease 300 is selected to carry out clinical observation, patient is randomly divided into two groups, and treatment group 300 respectively controls
1. treatment group is organized and 2. group, per group of 100 people, matched group 100, the factor such as each group patient medical record, age, sex, health basic
Cause, without significant difference, with comparability.
11.2, Therapeutic Method：
Treatment group's 1. group：Chinese medicine granules prepared by the oral embodiment of the present invention 3, each 20g, 3 times a day, is within 7 days one
The course for the treatment of, continuously takes 3 courses for the treatment of；Chinese medicine granules prepared by the oral embodiment of the present invention 3 of the previous hour of ultrasonic examination.
Treatment group's 2. group：Powder prepared by the oral embodiment of the present invention 7, each 20g, 3 times a day, is within 7 days a course for the treatment of, even
It is continuous to take 3 courses for the treatment of；Powder prepared by the oral embodiment of the present invention 7 of the previous hour of ultrasonic examination.
Matched group patient：Omeprazole+JUYUANSUNMOSHABILI granule+amoxicillin and clavulanate is taken by therapeutic dose
Potassium, 10 days is a course for the treatment of, continuously takes 2 courses for the treatment of, the oral barium sulfate of the previous hour of ultrasonic examination.
11.3, Outcome measure：
Radiography is clear：Radiography is clear, and gastrointestinal observation is clear, and diseased region observes clear, image clearly, and the strong echo of point-like is anti-
Penetrate, coat of the stomach clear layer is visible, the imaging such as gastral cavity size, form, cardia, pylorus, gastric antrum, duodenum, lesser gastric curvature, greater gastric curvature
Substantially, each position focus is high-visible.
Radiography is substantially clear：Radiography is substantially clear, and gastrointestinal observation is substantially clear, and diseased region observes substantially clear, image
Substantially clear, the stronger reecho of point-like, coat of the stomach clear layer are visible, gastral cavity size, form, cardia, pylorus, gastric antrum, 12
The imaging such as duodenum 12, lesser gastric curvature, greater gastric curvature is more apparent, and each position focus is high-visible.
It is clear that radiography is smudgy：Radiography is obscured, and gastrointestinal observation is unclear, and diseased region observation is unclear, and echogenic dots is anti-
Penetrate weaker, coat of the stomach level is chaotic, the imaging such as gastral cavity size, form, cardia, pylorus, gastric antrum, duodenum, lesser gastric curvature, greater gastric curvature
Not substantially, each position focus is difficult to recognize.
11.4, visualisation
Treatment group：Radiography is clear 198, and radiography is substantially clear 2, radiography is smudgy clear 0；Matched group radiography is clear
77, radiography is substantially clear 15, radiography is smudgy clear 8,5 patient's reaction barium sulfate are difficult to swallow, and have vomiting anti-
Should, barium sulfate is taken in 1 hour for 3 and flow to caecum portion, it is difficult to observe clear.
11.5, therapeutic outcome：
Cure：Ulcer and inflammation disappear, stomach dull pain, dull pain, distending pain, burn sample pain etc. stomach pain disappear, stomach move
Power is recovered, and metabolism recovers normal.
Take a turn for the better：Ulcer disappears or ulcer area reduces more than 50%, and its surrounding tissue inflammatory reaction mitigates or disappears, stomach
Uncomfortable to mitigate, gastric motility has recovered.
It is invalid：Ulcer area is unchanged or diminution is less than 50% or symptom is unchanged.
1. group is treated wherein through treatment：Cure 88, take a turn for the better 11, invalid 1, cure rate is 88%, total effective rate
For 99%；Treat 2. group：Cure 85, take a turn for the better 14, invalid 1, cure rate is 85%, and total effective rate is 99%；Matched group：
Cure 50, take a turn for the better 37, invalid 13, cure rate is 50%, and total effective rate is 87%.Result above shows, treatment group
Cure rate and total effective rate are apparently higher than matched group.
The follow-up individual treatment effect of 2 treatment group of table and matched group is as follows
| Group | Follow-up is individual | Relapse individual | Relapse rate |
| Treat 1. group | 88 | 0 | 0 |
| Treat 2. group | 84 | 1 | 1.19% |
| Matched group | 43 | 11 | 25.58% |
Can be seen by table 2：Scope follow-up is carried out during to ulcer healing patient 12 months after the course for the treatment of terminates, statistics is burst
Infectionss relapse rate.Wherein treat 1. organize 88 acquisition follow-ups, treatment 2. organize 85 acquisition follow-ups, 43 people of matched group healing person obtain with
Visit, two groups of gastric ulcer recurrence rates are relatively shown in Table 2.Above test result indicate that, Chinese medicine composition of the present invention is for gastric ulcer
It is during treatment, high with cure rate, the advantage for recurring is difficult, every statistical data is all due to western medicine matched group.
11.6, typical case
Case 1：Zou, female 40 years old, people from Nanchang, 2014 Nian Lai our hospital check that the long-term anorexia of patient, body weight only have 45
Kilogram, the nearest a period of time stomach indigestion of main suit is had a stomachache often, and the contrast agent of oral embodiment 3 during inspection goes out without vomiting situation
Existing, radiography is clear, and stomach is in fishhook-type, on an empty stomach without stomach pool stream；Antrum pleat irregular arrangement, increases thick.Coat of the stomach wriggling compared with
Difference, pyloric cap form are normal, and tentative diagnosis is chronic property gastritis, and in checking process, patient's oral account stomachache has mitigation, and
Without sense of discomfort, the desire eaten is wanted in inspection again after finishing.
Claims (9)
1. a kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent, it is characterised in that：Described pharmaceutical preparation includes following Chinese crude drug：It is precious
Pearl oyster, Mytilus, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Folium Malvae, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Herba Thesii, Herba Euphorbiae supinae, Radix Codonopsis lanceolatae,
Herba Tropaeoli.
2. pharmaceutical preparation according to claim 1, it is characterised in that described pharmaceutical preparation includes following weight portion Chinese medicine
Material：Concha Margaritifera 15-25 parts, Mytilus 15-30 parts, Rhizoma Chuanxiong 12-16 parts, Radix Sanguisorbae 6-12 parts, Semen Cuscutae 5-12 parts, Semen Euryaless 4-11 parts,
Folium Malvae 10-20 parts, Semen Ziziphi Spinosae 8-15 parts, Radix Glycyrrhizae 6-12 parts, Radix Scutellariae 5-10 parts, Herba Thesii 7-14 parts, Herba Euphorbiae supinae 3-8 parts, mountain
Carnis Rapanae thomasianae 6-11 parts, Herba Tropaeoli 6-14 parts.
3. pharmaceutical preparation according to claim 1, it is characterised in that described pharmaceutical preparation includes following weight portion Chinese medicine
Material：18 parts of Concha Margaritifera, 22 parts of Mytilus, 14 parts of Rhizoma Chuanxiong, 9 parts of Radix Sanguisorbae, 8.5 parts of Semen Cuscutae, 7.5 parts of Semen Euryaless, 15 parts of Folium Malvae, Ziziphi Spinosae
12.5 parts of core, 9 parts of Radix Glycyrrhizae, 7.5 parts of Radix Scutellariae, 10.5 parts of Herba Thesii, 6 parts of Herba Euphorbiae supinae, 8 parts of Radix Codonopsis lanceolatae, 10 parts of Herba Tropaeoli.
4. pharmaceutical preparation according to claim 1, it is characterised in that described pharmaceutical preparation includes following weight portion Chinese medicine
Material：20 parts of Concha Margaritifera, 20 parts of Mytilus, 13 parts of Rhizoma Chuanxiong, 10 parts, 9.5 parts of Semen Cuscutae, 7.5 parts of Semen Euryaless, 16 parts of Folium Malvae, Ziziphi Spinosae
13.5 parts of core, 10 parts of Radix Glycyrrhizae, 8.5 parts of Radix Scutellariae, 9.5 parts of Herba Thesii, 6.5 parts of Herba Euphorbiae supinae, 8.5 parts of Radix Codonopsis lanceolatae, 11 parts of Herba Tropaeoli.
5. a kind of pharmaceutical preparation prepared described in claim 1-4, it is characterised in that concrete step is：
1) each crude drug is filtered out according to each proportioning raw materials, it is standby after remove impurity；
2) by Mytilus, Folium Malvae, Herba Thesii, Herba Euphorbiae supinae and Herba Tropaeoli be put into 1500ml it is pure in, after slow fire is fried open, then slowly decoct 30
Minute, decocting liquid 500ml is poured out, the pure water of 300ml is added, it is slow to decoct 20 minutes, then decocting liquid 200ml is poured out, add 500ml
Water, continue it is slow decoct 30 minutes, decocting liquid is poured out, is mixed with the front decocting liquid poured out twice and is stirred evenly；
3) step 2) raw material concentrating under reduced pressure obtains condensed cream；
4) weigh appropriate Concha Margaritifera, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Radix Codonopsis lanceolatae respectively to be dried,
80～120 sieves were crushed, mixed powder was obtained, it is standby
5), after condensed cream is dried, smashing and step 4) mixed powder mixs homogeneously, and obtains final product powder.
6. a kind of pharmaceutical preparation prepared described in claim 1-4, it is characterised in that concrete step is：
1) each crude drug is filtered out according to each proportioning raw materials, it is standby after remove impurity；
2) by Mytilus, Folium Malvae, Herba Thesii, Herba Euphorbiae supinae and Herba Tropaeoli be put into 1500ml it is pure in, after slow fire is fried open, then slowly decoct 30
Minute, decocting liquid 500ml is poured out, the pure water of 300ml is added, it is slow to decoct 20 minutes, then decocting liquid 200ml is poured out, add 500ml
Water, continue it is slow decoct 30 minutes, decocting liquid is poured out, is mixed with the front decocting liquid poured out twice and is stirred evenly；
3) step 2) raw material concentrating under reduced pressure obtains condensed cream；
4) weigh appropriate Concha Margaritifera, Rhizoma Chuanxiong, Radix Sanguisorbae, Semen Cuscutae, Semen Euryaless, Semen Ziziphi Spinosae, Radix Glycyrrhizae, Radix Scutellariae, Radix Codonopsis lanceolatae respectively to be dried,
80～120 sieves were crushed, mixed powder was obtained, it is standby
5), after condensed cream is dried, smashing and step 4) mixed powder mixs homogeneously, pelletizes, and vacuum drying, granulate obtain final product granule
Agent.
7. pharmaceutical preparation according to claim 6, it is characterised in that step 5) described in granule often wrap weight 10g, it is described
Vacuum drying temperature control at 40-50 DEG C.
8. pharmaceutical preparation according to claim 1, it is characterised in that：Described pharmaceutical preparation helps shadow preparing gastrointestinal color ultrasound
Application in agent.
9. pharmaceutical preparation according to claim 1, it is characterised in that：Described pharmaceutical preparation is preparing treatment gastrointestinal disease
Application in medicine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610219162.3A CN105879065A (en) | 2016-04-08 | 2016-04-08 | Medicinal preparation for contrast media for gastrointestinal color Doppler ultrasound and preparation methods of medicinal preparation |
| CN2016102191623 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106540279A true CN106540279A (en) | 2017-03-29 |
Family
ID=57012812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610219162.3A Pending CN105879065A (en) | 2016-04-08 | 2016-04-08 | Medicinal preparation for contrast media for gastrointestinal color Doppler ultrasound and preparation methods of medicinal preparation |
| CN201611057761.6A Withdrawn CN106540279A (en) | 2016-04-08 | 2016-11-27 | A kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent and preparation method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610219162.3A Pending CN105879065A (en) | 2016-04-08 | 2016-04-08 | Medicinal preparation for contrast media for gastrointestinal color Doppler ultrasound and preparation methods of medicinal preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105879065A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422622A (en) * | 2008-12-09 | 2009-05-06 | 秦峰 | B-ultrasonic traditional Chinese medicine imaging assistant and preparation method thereof |
| CN102068707A (en) * | 2011-01-10 | 2011-05-25 | 张洪英 | Traditional Chinese medicine contrast medium adjuvant used for B ultrasonic and preparation method thereof |
| CN103495187A (en) * | 2013-10-04 | 2014-01-08 | 王发芬 | Type-B ultrasonic traditional Chinese medicinal gastroenterography assistant and method for preparing same |
| CN104258429A (en) * | 2014-09-16 | 2015-01-07 | 济南伟传信息技术有限公司 | Traditional Chinese medicine developing aid for B-ultrasound |
| CN104353089A (en) * | 2014-10-14 | 2015-02-18 | 刘树芹 | Color Doppler ultrasound contrast medium comprising traditional Chinese medicines as well as application and preparation method of medium |
-
2016
- 2016-04-08 CN CN201610219162.3A patent/CN105879065A/en active Pending
- 2016-11-27 CN CN201611057761.6A patent/CN106540279A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422622A (en) * | 2008-12-09 | 2009-05-06 | 秦峰 | B-ultrasonic traditional Chinese medicine imaging assistant and preparation method thereof |
| CN102068707A (en) * | 2011-01-10 | 2011-05-25 | 张洪英 | Traditional Chinese medicine contrast medium adjuvant used for B ultrasonic and preparation method thereof |
| CN103495187A (en) * | 2013-10-04 | 2014-01-08 | 王发芬 | Type-B ultrasonic traditional Chinese medicinal gastroenterography assistant and method for preparing same |
| CN104258429A (en) * | 2014-09-16 | 2015-01-07 | 济南伟传信息技术有限公司 | Traditional Chinese medicine developing aid for B-ultrasound |
| CN104353089A (en) * | 2014-10-14 | 2015-02-18 | 刘树芹 | Color Doppler ultrasound contrast medium comprising traditional Chinese medicines as well as application and preparation method of medium |
Non-Patent Citations (1)
| Title |
|---|
| 张炳盛 等主编.: "《中药学专业知识》", 30 April 2007, 中国中医药出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105879065A (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068707B (en) | Traditional Chinese medicine contrast medium adjuvant used for B ultrasonic and preparation method thereof | |
| CN102949734B (en) | Traditional Chinese medicine gastrointestinal auxiliary for type-B ultrasonic and preparation method thereof | |
| CN101797326B (en) | Chinese materia medica preparation for treating borborygmus diarrhoea and preparation method thereof | |
| CN107441409A (en) | Chinese medicine composition for treating habitual constipation and preparation method thereof | |
| CN103041256A (en) | Chinese herb preparation for curing recurrent respiratory tract infection of children | |
| CN100509034C (en) | Medicine for treating chronic atrophic gastritis | |
| CN103041257A (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
| CN103272189B (en) | Medicine for curing gallstones | |
| CN104645232A (en) | Traditional Chinese medicine combinatorial composition for treatment of double-flexure syndrome and preparation method and applications thereof | |
| CN104587166A (en) | Traditional Chinese medicine preparation for treating postpartum, and preparation method | |
| CN107890521A (en) | A kind of Chinese medicine composition of liver protection and eyesight and its preparation method of pill | |
| CN104189805B (en) | A kind of Chinese medicine composition and preparation method thereof for treating children's sexual precocity | |
| CN103041255A (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
| CN105770920B (en) | A kind of pharmaceutical preparation and its application for stomach and intestine color ultrasound assistant | |
| CN106540279A (en) | A kind of pharmaceutical preparation of gastrointestinal color ultrasound contrast agent and preparation method thereof | |
| CN104435962A (en) | Pharmaceutical composition for treating dyspeptic diarrhea of piglets and preparation method thereof | |
| CN103830750B (en) | A kind of gastrointestinal contrast agent containing Chinese medicine extract | |
| CN102805826B (en) | Drug for reducing weight and beautifying facial appearance and preparation method thereof | |
| CN103860844B (en) | A kind of Chinese medicine preparation for the treatment of chronic colitis and preparation method thereof | |
| CN102580032A (en) | Chinese medicinal composition tablets, powder and oral liquid with effect of promoting urinary calculus removal and preparation method thereof | |
| CN106692858A (en) | Medicine for treating threatened abortion and preparation method of medicine | |
| CN106955348A (en) | Chinese medicine composition and preparation method for treating chronic nephritis | |
| CN105596813A (en) | Method used for painless removing of kidney stone with traditional Chinese medicines, and medicine taking method | |
| CN105125945B (en) | A kind of row's stone drink and preparation method thereof for treating kidney stone | |
| CN104940777A (en) | Electuary capable of treating liver-yang hyperactivity and spleen weakness type diarrhea during menstruation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170329 |